PCM
TEVA icon

Prelude Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Prelude Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$1K – 2334
2020
Q2 		$1K Sell
100
-2,900
-97% -$32.8K ﹤0.01% 1889
2020
Q1 		$27K Buy
3,000
+2,600
+650% +$26.6K ﹤0.01% 911
2019
Q4 		$4K Buy
+400
New +$3.57K ﹤0.01% 1792
2019
Q2 		– Sell
-200
Closed -$3K – 2135
2019
Q1 		$3K Buy
+200
New +$3.53K ﹤0.01% 1672
2018
Q4 		– Sell
-60,000
Closed -$1.29M – 2147
2018
Q3 		$1.29M Buy
+60,000
New +$1.39M 0.08% 299

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Prelude Capital Management's TEVA Position: Q2 2026 in Review

Prelude Capital Management held its Teva Pharmaceutical Industries Limited (TEVA) position steady in Q2 2026 at 154,970 shares worth $5.25M. The position accounts for 0.38% of the portfolio, ranked #48.

Prelude Capital Management first reported a position in TEVA in Q2 2014 and has held it in 27 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Prelude Capital Management held 154,970 shares of Teva Pharmaceutical Industries Limited worth $5.25M as of Q2 2026.
  • Prelude Capital Management left its Teva Pharmaceutical Industries Limited share count unchanged in Q2 2026.
  • Teva Pharmaceutical Industries Limited made up 0.38% of Prelude Capital Management's portfolio in Q2 2026, its #48 holding.
  • Prelude Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2014 and has held it in 27 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.